

Subject Company: Ritter Pharmaceuticals, Inc. (SEC File No. 001-37428)
Commission File No. for the Related Registration Statement: 333-236235



Dear Ritter Pharmaceuticals, Inc. Stockholder,

You recently received proxy materials pertaining to certain matters related to **Ritter Pharmaceuticals, Inc.'s** (the "Company" or "Ritter") proposed merger with Qualigen, Inc. (the "Merger Proposals") to be voted on at a **Special Meeting of Stockholders of Ritter**, which will be held virtually on **May 14, 2020**, at 9:00 a.m., Pacific Time.

You are receiving this **REMINDER** notice because you held shares of Ritter as of the close of business on March 26, 2020, the record date for the Special Meeting, and *have not yet received your vote*.

The Board of Directors of the Company unanimously recommends that you vote "FOR" each of the Merger Proposals to be considered at the Special Meeting.

HOW TO VOTE

Record Holders:

- Vote NOW by telephone (800) 690-6903 or via the internet (www.proxyvote.com), by following the instructions on the enclosed proxy card, which provides your control number.
- Complete, sign and date the enclosed proxy card and mail it in the enclosed postage-paid envelope as soon as possible.

Beneficial (Street) Holders:

If you hold your shares in a brokerage or bank account (in "street name"), your broker or bank cannot vote your shares unless you complete, sign and date the enclosed voting instruction form and return the form to your bank or broker, or vote online or by phone, by following the instructions provided in the voting instruction form.

REASONS TO VOTE "FOR" THE MERGER PROPOSALS

- The merged company will focus on the development of Qualigen's nanotechnology therapies for the treatment of cancer and infectious diseases, while continuing to operate its revenue-generating diagnostic business.
- Ritter shareholders will own 7.5% of the post-merger company and will receive Contingent Value Rights (CVRs), entitling them to a portion of the net proceeds from any potential monetization event involving all or any part of Ritter's intellectual property or technology.¹

Your vote is very important, no matter how large or small your holdings may be. Each of Proposal Nos. 1, 2, 3 and 4 are conditioned upon each other. Therefore, the merger cannot be consummated without the approval of Proposal Nos. 1, 2, 3 and 4. Your failure to vote, or your decision to abstain from voting, will have the same effect as a vote **AGAINST** the Merger Proposals, which will, collectively, have the effect of voting **AGAINST** the merger.

YOUR VOTE MATTERS!!! VOTING NOW HELPS ELIMINATE FURTHER REMINDER MAILINGS & PHONE CALLS

If you have questions or need assistance in voting your shares, please call Georgeson LLC at 1-866-357-4029.

A handwritten signature in blue ink that reads "Andrew J. Ritter".

Sincerely,
Andrew J. Ritter
Chief Executive Officer
Ritter Pharmaceuticals, Inc.

¹ To better understand the merger and the proposals being considered at the Special Meeting, please carefully read the entire joint proxy and consent solicitation statement/prospectus that was delivered to you, including the Merger Agreement attached as Annex A and the amendments to the Merger Agreement attached as Annex B and Annex C and the other annexes to the Merger Agreement.